Brainsway Ltd.
Develops noninvasive neurostimulation treatments for mental health and addiction.
BWAY | TA
Overview
Corporate Details
- ISIN(s):
- IL0011007189
- LEI:
- Country:
- Israel
- Address:
- 16 Hartum St, 9777516 Har Hotzvim, Jerusalem
- Website:
- https://www.brainsway.com/
- Sector:
- Manufacturing
Description
Brainsway Ltd. is a medical technology company focused on developing and marketing advanced noninvasive neurostimulation treatments for mental health and addictive disorders. The company's core product is its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) system, which uses a patented H-coil to stimulate deeper and broader regions of the brain. The technology is designed as a safe and effective non-drug treatment option. The Deep TMS system has received multiple FDA clearances for conditions including Major Depressive Disorder (MDD), anxious depression, and Obsessive-Compulsive Disorder (OCD), for which it was the first noninvasive medical device to receive such clearance. It is also FDA-cleared as an aid for short-term smoking cessation, the first TMS device to be cleared for an addiction indication.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-06-17 16:29 |
BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreeme…
|
English | 53.8 KB | ||
| 2024-06-17 16:29 |
BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreeme…
|
English | 36.4 KB | ||
| 2024-06-10 16:29 |
Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating
Acce…
|
English | 51.7 KB | ||
| 2024-06-10 16:29 |
Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating
Acce…
|
English | 36.5 KB | ||
| 2024-06-03 16:29 |
BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression
|
English | 53.0 KB | ||
| 2024-06-03 16:29 |
BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression
|
English | 36.4 KB | ||
| 2024-05-10 01:00 |
Immediate Report of Meeting to be held on June 17, 2024, proxy
|
English | 484.0 KB | ||
| 2024-05-10 01:00 |
Immediate Report of Meeting to be held on June 17, 2024, proxy
|
English | 483.8 KB | ||
| 2024-05-10 01:00 |
Immediate Report of Meeting to be held on June 17, 2024, proxy
|
English | 180.9 KB | ||
| 2024-05-08 16:29 |
First Quarter 2024 Financial Results and Operational Highlights
|
English | 527.4 KB | ||
| 2024-05-08 16:29 |
First Quarter 2024 Financial Results and Operational Highlights
|
English | 36.4 KB | ||
| 2024-04-17 16:59 |
BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in …
|
English | 45.9 KB | ||
| 2024-04-17 16:59 |
BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in …
|
English | 36.4 KB | ||
| 2024-04-04 16:59 |
Announces Published Review Results Highlighting Potential of Deep TMS™ to
Treat…
|
English | 114.6 KB | ||
| 2024-04-04 16:59 |
Announces Published Review Results Highlighting Potential of Deep TMS™ to
Treat…
|
English | 36.5 KB |
Automate Your Workflow. Get a real-time feed of all Brainsway Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Brainsway Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Brainsway Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
